hercessi
Pharmaranks rates Hercessi 3.5/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Hercessi (Trastuzumab-Strf) is a HER2/neu receptor antagonist used to treat Breast Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms.
Trastuzumab-Strf · by Accord Biopharma Inc.
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Trastuzumab-Strf
- Drug class
- Her2/Neu Receptor Antagonist
- Form
- Injectable
- Strength
- TRASTUZUMAB-STRF 150MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Accord Biopharma Inc.
- FDA application
- BLA761346
Drug class
May treat (source: NIH RxClass)
See how Hercessi ranks — best-rated HER2/neu receptor antagonist for:
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Hercessi treat?
- Hercessi (Trastuzumab-Strf) may be used to treat breast neoplasms, gastrointestinal neoplasms, stomach neoplasms, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Hercessi rated?
- pharmaranks gives Hercessi a composite score of 3.5 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Hercessi?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Hercessi. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Hercessi?
- Hercessi is marketed by Accord Biopharma Inc.. You can see Accord Biopharma Inc.'s full profile, rating, and other products on pharmaranks.
- Is Hercessi a brand-name or generic drug?
- Hercessi is a brand-name product with the active ingredient Trastuzumab-Strf.
- Is Hercessi available over the counter?
- No. Hercessi is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Hercessi come in?
- Hercessi is currently marketed as injectable, per the FDA's National Drug Code Directory.
- What class of drug is Hercessi?
- Hercessi is classified as her2/neu receptor antagonist, per the FDA's Established Pharmacologic Class.
- Is Hercessi FDA-registered?
- Hercessi is on record with the U.S. FDA under application number BLA761346. You can verify this on its official FDA label.
- Has Hercessi been recalled by the FDA?
- Hercessi has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Hercessi safe?
- There's no single safe-or-not verdict. pharmaranks gives Hercessi a recall-safety score of 70/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about TRASTUZUMAB-STRF
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 4 reports naming TRASTUZUMAB-STRF — the active ingredient in Hercessi, and the FDA flagged 100% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- diarrhoea2 reports
- leukopenia2 reports
- neutropenia2 reports
- thrombocytopenia2 reports
- vomiting2 reports
- alanine aminotransferase increased1 reports
- alopecia1 reports
- anaemia1 reports
Read these as a signal, not a rate. A report does not mean TRASTUZUMAB-STRF caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Hercessi head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
hercessi
70/100